DrugCards

DrugCards DrugCard is a cost-effective full-regulatory compliant software for pharma drug safety departments

๐Ÿ‡บ๐Ÿ‡ฆ ะŸะฐั€ั‚ะฝะตั€ ัะพั†ั–ะฐะปัŒะฝะพะณะพ ะฒะฟะปะธะฒัƒ   โ€” ั–ะฝั–ั†ั–ะฐั‚ะธะฒะฐ ะ”ะพะฝะพั€UAะœะธ ั€ะฐะดั– ะฟะพะดั–ะปะธั‚ะธัั ั‡ัƒะดะพะฒะพัŽ ะฝะพะฒะธะฝะพัŽ! ะะฐ ะฝะฐัˆั–ะน ะบะพะฝั„ะตั€ะตะฝั†ั–ั— ะฑัƒะดะต ะฟั€ะตะดัั‚...
27/11/2025

๐Ÿ‡บ๐Ÿ‡ฆ ะŸะฐั€ั‚ะฝะตั€ ัะพั†ั–ะฐะปัŒะฝะพะณะพ ะฒะฟะปะธะฒัƒ โ€” ั–ะฝั–ั†ั–ะฐั‚ะธะฒะฐ ะ”ะพะฝะพั€UA
ะœะธ ั€ะฐะดั– ะฟะพะดั–ะปะธั‚ะธัั ั‡ัƒะดะพะฒะพัŽ ะฝะพะฒะธะฝะพัŽ! ะะฐ ะฝะฐัˆั–ะน ะบะพะฝั„ะตั€ะตะฝั†ั–ั— ะฑัƒะดะต ะฟั€ะตะดัั‚ะฐะฒะปะตะฝะฐ ะบะพะผะฐะฝะดะฐ ะ”ะพะฝะพั€UA โ€” ะฟะตั€ัˆะพั— ั‚ะฐ ั”ะดะธะฝะพั— ะฒ ะฃะบั€ะฐั—ะฝั– ั†ะธั„ั€ะพะฒะพั— ะตะบะพัะธัั‚ะตะผะธ ะดะปั ั€ะตะบั€ัƒั‚ะธะฝะณัƒ ั‚ะฐ ะบะพะพั€ะดะธะฝะฐั†ั–ั— ะดะพะฝะพั€ั–ะฒ ะบั€ะพะฒั–.
ะ— 2015 ั€ะพะบัƒ ะฒะพะฝะธ ะพะฑโ€™ั”ะดะฝัƒัŽั‚ัŒ ะดะพะฝะพั€ั–ะฒ, ะปั–ะบะฐั€ะฝั– ั‚ะฐ ะฟะฐั†ั–ั”ะฝั‚ั–ะฒ, ั„ะพั€ะผัƒัŽั‡ะธ ะบัƒะปัŒั‚ัƒั€ัƒ ัะฒั–ะดะพะผะพะณะพ ั‚ะฐ ั€ะตะณัƒะปัั€ะฝะพะณะพ ะดะพะฝะพั€ัั‚ะฒะฐ.
ะกัŒะพะณะพะดะฝั– ะฝะฐ ะฟะปะฐั‚ั„ะพั€ะผั– ะฒะถะต ะฟะพะฝะฐะด 200 000 ะบะพั€ะธัั‚ัƒะฒะฐั‡ั–ะฒ, ัะบั– ะดะพะฟะพะผะฐะณะฐัŽั‚ัŒ ั€ัั‚ัƒะฒะฐั‚ะธ ะถะธั‚ั‚ั ะฟะพ ะฒัั–ะน ะบั€ะฐั—ะฝั–.
๐Ÿฉธ ะŸั–ะด ั‡ะฐั ะฟะพะดั–ั— ะฟั€ะฐั†ัŽะฒะฐั‚ะธะผะต ะทะพะฝะฐ โ€œะœะพั ะณั€ัƒะฟะฐ ะบั€ะพะฒั–โ€
ะšะพะถะตะฝ ะพั…ะพั‡ะธะน ะทะผะพะถะต ะฒะธะทะฝะฐั‡ะธั‚ะธ ัะฒะพัŽ ะณั€ัƒะฟัƒ ะบั€ะพะฒั– ะทะฐ ะดะพะฟะพะผะพะณะพัŽ ัˆะฒะธะดะบะธั… ั‚ะตัั‚ั–ะฒ Eldon Card ั–, ะทะฐ ะฑะฐะถะฐะฝะฝัะผ, ะดะพะปัƒั‡ะธั‚ะธัั ะดะพ ะฑะฐะทะธ ะดะพะฝะพั€ั–ะฒ.
ะœะฐะปะตะฝัŒะบะธะน ะบั€ะพะบ ะผะพะถะต ะทะผั–ะฝะธั‚ะธ ั‡ะธัŽััŒ ะดะพะปัŽ โค๏ธ
ะ ะตั”ัั‚ั€ะฐั†ั–ั ั‚ั€ะธะฒะฐั” โ€” ะฟั€ะธั”ะดะฝัƒะนั‚ะตััŒ!
๐Ÿ‘‰ https://drugcards-26507628.hubspotpagebuilder.eu/drug...

๐Ÿ‡ฌ๐Ÿ‡งOur Social Impact Partner for โ€” DonorUA
Weโ€™re happy to share that DonorUA will join our conference as a Social Impact Partner.
DonorUA is the first and only digital ecosystem in Ukraine designed to recruit and coordinate blood donors โ€” a platform that has been shaping a culture of conscious, regular blood donation since 2015.
Today, DonorUA brings together more than 200,000 users across the country, helping hospitals and patients receive donor blood safely and on time.
๐Ÿฉธ At the conference, youโ€™ll find the โ€œMy Blood Typeโ€ zone, where anyone can quickly determine their blood type using Eldon Card rapid tests and, if willing, sign up as a potential donor.
A small action can save someoneโ€™s life โค๏ธ
Registration for the conference is open โ€” join us!
๐Ÿ‘‰ https://drugcards-26507628.hubspotpagebuilder.eu/drug...

English version below. ๐Ÿ“„ ะ”ั€ัƒะทั–, ะผะฐั”ะผะพ ั‡ัƒะดะพะฒัƒ ะฝะพะฒะธะฝัƒ!ะฃ ะฉะพั‚ะธะถะฝะตะฒะธะบัƒ ยซะะฟั‚ะตะบะฐยป ะฒะธะนัˆะปะฐ ะฝะพะฒะฐ ัั‚ะฐั‚ั‚ั ะฟั€ะพ ั‚ะต, ัะบ ั„ะพั€ะผะฐั‚ eCTD ะทะผั–...
25/11/2025

English version below. ๐Ÿ“„ ะ”ั€ัƒะทั–, ะผะฐั”ะผะพ ั‡ัƒะดะพะฒัƒ ะฝะพะฒะธะฝัƒ!
ะฃ ะฉะพั‚ะธะถะฝะตะฒะธะบัƒ ยซะะฟั‚ะตะบะฐยป ะฒะธะนัˆะปะฐ ะฝะพะฒะฐ ัั‚ะฐั‚ั‚ั ะฟั€ะพ ั‚ะต, ัะบ ั„ะพั€ะผะฐั‚ eCTD ะทะผั–ะฝัŽั” ะฟั€ะพั†ะตั ั€ะตั”ัั‚ั€ะฐั†ั–ั— ะปั–ะบั–ะฒ ะฒ ะฃะบั€ะฐั—ะฝั– โ€” ั– ัะบ ะผะธ ั€ะตะฐะปั–ะทัƒะฒะฐะปะธ ั†ะตะน ะฟั–ะดั…ั–ะด ัƒ DrugCard.

ะฃ ะผะฐั‚ะตั€ั–ะฐะปั– ั€ะพะทะฟะพะฒั–ะดะฐั”ะผะพ, ัะบ ั†ะธั„ั€ะพะฒะต ะฟะพะดะฐะฝะฝั ะดะพััŒั” ะฟั€ะฐั†ัŽั” ะฝะฐ ะฟั€ะฐะบั‚ะธั†ั–, ั‡ะพะผัƒ ั†ะต ัะฟั€ะพั‰ัƒั” ั€ะพะฑะพั‚ัƒ ะบะพะผะฟะฐะฝั–ะน ั‚ะฐ ัะบ ะดะพะฟะพะผะฐะณะฐั” ั€ัƒั…ะฐั‚ะธัั ะดะพ ั”ะฒั€ะพั–ะฝั‚ะตะณั€ะฐั†ั–ั—.

ะ—ะฐะฟั€ะพัˆัƒั”ะผะพ ะดะพ ะฟั€ะพั‡ะธั‚ะฐะฝะฝั ๐Ÿ‘‡

๐Ÿ“„ Great news! Our new article has just been published in Shchotyzhnevyk Apteka, covering how the eCTD format is transforming the medicinal product registration process in Ukraine โ€” and how weโ€™ve built this workflow inside DrugCard.

The piece explains how digital dossier submission works in practice, why it simplifies the work for pharma companies, and how it supports Ukraineโ€™s move toward EU alignment.

I invite you to check it out ๐Ÿ‘‡

18 ัะตั€ะฟะฝั 2025 ั€. ะฃะบั€ะฐั—ะฝะฐ ะพั„ั–ั†ั–ะนะฝะพ ะฟะตั€ะตะนัˆะปะฐ ะฝะฐย ั„ะพั€ะผะฐั‚ ะตะปะตะบั‚ั€ะพะฝะฝะพะณะพ ะทะฐะณะฐะปัŒะฝะพะณะพ ั‚ะตั…ะฝั–ั‡ะฝะพะณะพ ะดะพะบัƒะผะตะฝั‚ะฐ (electronic Common Technical Document โ€” eCTD) โ€” ะผั–ะถะฝะฐั€ะพะดะฝะธะน ัั‚ะฐะฝะดะฐั€ั‚ ะตะปะตะบั‚ั€ะพะฝะฝะพะณะพ ...

๐—ฃ๐—ต๐—ฎ๐—ฟ๐—บ๐—ฎ๐—ฐ๐—ผ๐˜ƒ๐—ถ๐—ด๐—ถ๐—น๐—ฎ๐—ป๐—ฐ๐—ฒ ๐—ท๐˜‚๐˜€๐˜ ๐—ด๐—ผ๐˜ ๐—ฎ ๐—บ๐—ฎ๐—ท๐—ผ๐—ฟ ๐˜‚๐—ฝ๐—ด๐—ฟ๐—ฎ๐—ฑ๐—ฒ!Remember when monitoring medical literature meant dozens of tabs and endless ...
25/11/2025

๐—ฃ๐—ต๐—ฎ๐—ฟ๐—บ๐—ฎ๐—ฐ๐—ผ๐˜ƒ๐—ถ๐—ด๐—ถ๐—น๐—ฎ๐—ป๐—ฐ๐—ฒ ๐—ท๐˜‚๐˜€๐˜ ๐—ด๐—ผ๐˜ ๐—ฎ ๐—บ๐—ฎ๐—ท๐—ผ๐—ฟ ๐˜‚๐—ฝ๐—ด๐—ฟ๐—ฎ๐—ฑ๐—ฒ!
Remember when monitoring medical literature meant dozens of tabs and endless PDFs?
๐Ÿ“ขGood news - those days are gone!

๐Ÿ”ฅOur latest blog post explores how the DrugCard platformโ€™s new AI literature screening features are revolutionising pharmacovigilance. From smart prioritisation with the red man alerts to AI-generated summaries and instant collaboration, specialists can now focus on what truly matters: patient safety.

๐Ÿš€Curious how AI is reshaping the world of drug safety? Check out the full story and see why mornings in pharmacovigilance are now faster, wiser, and way more interesting.
๐Ÿ”— Read the full article on our blog: https://drug-card.io/blog/pharmacovigilance-made-smarter-with-new-ai-literature-screening-on-the-platform/

๐ŸŒŸ ๐—œ๐—ป ๐˜๐—ต๐—ฒ๐˜€๐—ฒ ๐—ฐ๐—ต๐—ฎ๐—น๐—น๐—ฒ๐—ป๐—ด๐—ถ๐—ป๐—ด ๐˜๐—ถ๐—บ๐—ฒ๐˜€ ๐—ณ๐—ผ๐—ฟ ๐—จ๐—ธ๐—ฟ๐—ฎ๐—ถ๐—ป๐—ฒ, ๐˜€๐˜๐—ฎ๐˜†๐—ถ๐—ป๐—ด ๐—ฐ๐—ผ๐—ป๐—ป๐—ฒ๐—ฐ๐˜๐—ฒ๐—ฑ ๐—ฎ๐—ป๐—ฑ ๐˜€๐˜‚๐—ฝ๐—ฝ๐—ผ๐—ฟ๐˜๐—ถ๐—ป๐—ด ๐—ฒ๐—ฎ๐—ฐ๐—ต ๐—ผ๐˜๐—ต๐—ฒ๐—ฟ ๐—บ๐—ฎ๐˜๐˜๐—ฒ๐—ฟ๐˜€ ๐—บ๐—ผ๐—ฟ๐—ฒ ๐˜๐—ต๐—ฎ๐—ป ๐—ฒ๐˜ƒ๐—ฒ๐—ฟ.Thatโ€™s why ...
19/11/2025

๐ŸŒŸ ๐—œ๐—ป ๐˜๐—ต๐—ฒ๐˜€๐—ฒ ๐—ฐ๐—ต๐—ฎ๐—น๐—น๐—ฒ๐—ป๐—ด๐—ถ๐—ป๐—ด ๐˜๐—ถ๐—บ๐—ฒ๐˜€ ๐—ณ๐—ผ๐—ฟ ๐—จ๐—ธ๐—ฟ๐—ฎ๐—ถ๐—ป๐—ฒ, ๐˜€๐˜๐—ฎ๐˜†๐—ถ๐—ป๐—ด ๐—ฐ๐—ผ๐—ป๐—ป๐—ฒ๐—ฐ๐˜๐—ฒ๐—ฑ ๐—ฎ๐—ป๐—ฑ ๐˜€๐˜‚๐—ฝ๐—ฝ๐—ผ๐—ฟ๐˜๐—ถ๐—ป๐—ด ๐—ฒ๐—ฎ๐—ฐ๐—ต ๐—ผ๐˜๐—ต๐—ฒ๐—ฟ ๐—บ๐—ฎ๐˜๐˜๐—ฒ๐—ฟ๐˜€ ๐—บ๐—ผ๐—ฟ๐—ฒ ๐˜๐—ต๐—ฎ๐—ป ๐—ฒ๐˜ƒ๐—ฒ๐—ฟ.

Thatโ€™s why we decided to bring the Ukrainian pharmacovigilance community together and organise ๐—ฎ ๐—ณ๐—ฟ๐—ฒ๐—ฒ, ๐—ฝ๐—ฟ๐—ฎ๐—ฐ๐˜๐—ถ๐—ฐ๐—ฎ๐—น ๐—ฐ๐—ผ๐—ป๐—ณ๐—ฒ๐—ฟ๐—ฒ๐—ป๐—ฐ๐—ฒ focused on the technologies shaping our future.

๐—œ๐—ป๐˜๐—ฟ๐—ผ๐—ฑ๐˜‚๐—ฐ๐—ถ๐—ป๐—ด ๐—ž๐˜†๐—ถ๐˜ƒ ๐——๐—ฟ๐˜‚๐—ด ๐—ฆ๐—ฎ๐—ณ๐—ฒ๐˜๐˜† ๐——๐—ฎ๐˜† โ€” ๐—ฅ๐—ฒ๐—ด๐—ถ๐˜€๐˜๐—ฟ๐—ฎ๐˜๐—ถ๐—ผ๐—ป ๐—ถ๐˜€ ๐—ป๐—ผ๐˜„ ๐—ผ๐—ฝ๐—ฒ๐—ป!
๐Ÿ“… ๐Ÿญ๐Ÿญ ๐——๐—ฒ๐—ฐ๐—ฒ๐—บ๐—ฏ๐—ฒ๐—ฟ ๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฑ
๐Ÿ“ ๐—š๐—˜๐—ก๐—˜๐—ฅ๐—”๐—ง๐—ข๐—ฅ ๐—–๐—ผ๐˜„๐—ผ๐—ฟ๐—ธ๐—ถ๐—ป๐—ด, ๐—ž๐˜†๐—ถ๐˜ƒ (๐—›๐—ฟ๐˜‚๐˜€๐—ต๐—ฒ๐˜ƒ๐˜€๐—ธ๐—ผ๐—ต๐—ผ ๐Ÿฏ)
๐ŸŽŸ ๐—ฃ๐—ฎ๐—ฟ๐˜๐—ถ๐—ฐ๐—ถ๐—ฝ๐—ฎ๐˜๐—ถ๐—ผ๐—ป ๐—ถ๐˜€ ๐—ณ๐—ฟ๐—ฒ๐—ฒ โ€” ๐—ฟ๐—ฒ๐—ด๐—ถ๐˜€๐˜๐—ฟ๐—ฎ๐˜๐—ถ๐—ผ๐—ป ๐—ฟ๐—ฒ๐—พ๐˜‚๐—ถ๐—ฟ๐—ฒ๐—ฑ
๐Ÿ—ฃ ๐—ง๐—ต๐—ฒ ๐—ฒ๐˜ƒ๐—ฒ๐—ป๐˜ ๐˜„๐—ถ๐—น๐—น ๐—ฏ๐—ฒ ๐—ต๐—ฒ๐—น๐—ฑ ๐—ถ๐—ป ๐—จ๐—ธ๐—ฟ๐—ฎ๐—ถ๐—ป๐—ถ๐—ฎ๐—ป
๐Ÿ‡บ๐Ÿ‡ฆ ๐—™๐—ผ๐—ฟ ๐—จ๐—ธ๐—ฟ๐—ฎ๐—ถ๐—ป๐—ถ๐—ฎ๐—ป ๐—ฃ๐—ฉ ๐—ฝ๐—ฟ๐—ผ๐—ณ๐—ฒ๐˜€๐˜€๐—ถ๐—ผ๐—ป๐—ฎ๐—น๐˜€

This is the first event in Ukraine fully dedicated to ๐—ฎ๐˜‚๐˜๐—ผ๐—บ๐—ฎ๐˜๐—ถ๐—ผ๐—ป ๐—ฎ๐—ป๐—ฑ ๐˜๐—ต๐—ฒ ๐˜‚๐˜€๐—ฒ ๐—ผ๐—ณ ๐—”๐—œ ๐—ถ๐—ป ๐—ฝ๐—ต๐—ฎ๐—ฟ๐—บ๐—ฎ๐—ฐ๐—ผ๐˜ƒ๐—ถ๐—ด๐—ถ๐—น๐—ฎ๐—ป๐—ฐ๐—ฒ, created to share knowledge, exchange experience, and strengthen our professional community.

Whatโ€™s ahead:
๐Ÿ”น Practical expert talks
๐Ÿ”น A real automation case study by DrugCard
๐Ÿ”น Two panel discussions: AI regulation (EMA/FDA) & complex literature assessment
๐Ÿ”น Open Q&A forum
๐Ÿ”น Launch of the Secret Drug Safety Club UA
๐Ÿ”น Warm and purposeful networking

๐Ÿ‘‰ Register here: https://drugcards-26507628.hubspotpagebuilder.eu/drug_safety_day

We look forward to welcoming everyone who is moving Ukrainian pharmacovigilance forward โ€” together, even in difficult times ๐Ÿ’™๐Ÿ’›

๐—ช๐—ผ๐—ฟ๐—น๐—ฑ ๐—”๐— ๐—ฅ ๐—”๐˜„๐—ฎ๐—ฟ๐—ฒ๐—ป๐—ฒ๐˜€๐˜€ ๐—ช๐—ฒ๐—ฒ๐—ธ ๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฑ ๐—ฅ๐—ถ๐—ป๐—ด๐˜€ ๐˜๐—ต๐—ฒ ๐—”๐—ป๐˜๐—ถ๐—ฏ๐—ถ๐—ผ๐˜๐—ถ๐—ฐ ๐—”๐—น๐—ฎ๐—ฟ๐—บ๐ŸงซEvery year, drug-resistant infections claim 35,000 lives in Eur...
18/11/2025

๐—ช๐—ผ๐—ฟ๐—น๐—ฑ ๐—”๐— ๐—ฅ ๐—”๐˜„๐—ฎ๐—ฟ๐—ฒ๐—ป๐—ฒ๐˜€๐˜€ ๐—ช๐—ฒ๐—ฒ๐—ธ ๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฑ ๐—ฅ๐—ถ๐—ป๐—ด๐˜€ ๐˜๐—ต๐—ฒ ๐—”๐—ป๐˜๐—ถ๐—ฏ๐—ถ๐—ผ๐˜๐—ถ๐—ฐ ๐—”๐—น๐—ฎ๐—ฟ๐—บ๐Ÿงซ
Every year, drug-resistant infections claim 35,000 lives in Europe alone - yet the real danger isnโ€™t just resistance. Itโ€™s how quietly it grows.

โ€ผ๏ธBehind every unexpected loss of efficacy, every prescription given โ€œjust in case,โ€ and every overlooked pattern in medical literature, antimicrobial resistance is already shaping the future of medicine.
๐Ÿ“ขAnd this yearโ€™s theme - โ€œAct Now: Protect Our Present, Secure Our Futureโ€ - says it all.

๐Ÿ‘‰ Learn more in our latest blog article: https://drug-card.io/blog/listen-to-the-antibiotic-alarm-during-world-amr-awareness-week/

๐Ÿฆธโ€โ™‚๏ธ๐—ง๐—ต๐—ฒ ๐——๐—ฎ๐—ถ๐—น๐˜† ๐—Ÿ๐—ถ๐—ณ๐—ฒ ๐—ผ๐—ณ ๐—ฎ ๐—ฃ๐—ต๐—ฎ๐—ฟ๐—บ๐—ฎ๐—ฐ๐—ผ๐˜ƒ๐—ถ๐—ด๐—ถ๐—น๐—ฎ๐—ป๐—ฐ๐—ฒ ๐—ฆ๐—ฝ๐—ฒ๐—ฐ๐—ถ๐—ฎ๐—น๐—ถ๐˜€๐˜Being a pharmacovigilance specialist is more than just filling out r...
11/11/2025

๐Ÿฆธโ€โ™‚๏ธ๐—ง๐—ต๐—ฒ ๐——๐—ฎ๐—ถ๐—น๐˜† ๐—Ÿ๐—ถ๐—ณ๐—ฒ ๐—ผ๐—ณ ๐—ฎ ๐—ฃ๐—ต๐—ฎ๐—ฟ๐—บ๐—ฎ๐—ฐ๐—ผ๐˜ƒ๐—ถ๐—ด๐—ถ๐—น๐—ฎ๐—ป๐—ฐ๐—ฒ ๐—ฆ๐—ฝ๐—ฒ๐—ฐ๐—ถ๐—ฎ๐—น๐—ถ๐˜€๐˜
Being a pharmacovigilance specialist is more than just filling out reports or coding adverse events. Itโ€™s about detective work, critical thinking, and a deep commitment to patient safety.

From assessing complex causality cases ๐Ÿ•ต๏ธโ€โ™‚๏ธ, to monitoring medical literature for rare adverse reactions ๐Ÿ“š, to navigating endless regulatory deadlines โฐ - PV specialists see the side of drug safety that most people never notice.

๐Ÿ”ฅOur latest blog post dives into 7 things only pharmacovigilance specialists truly understand. This article gives a behind-the-scenes look into the everyday life of PV specialists.
๐Ÿ‘‰ Read the full article here: https://drug-card.io/blog/7-things-only-pharmacovigilance-specialist-truly-understand/

 #๐— ๐—ฒ๐—ฑ๐—ฆ๐—ฎ๐—ณ๐—ฒ๐˜๐˜†๐—ช๐—ฒ๐—ฒ๐—ธ ๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฑ ๐—ถ๐˜€ ๐—ต๐—ฒ๐—ฟ๐—ฒ! ๐Ÿšจโ€œ๐˜ž๐˜ฆ ๐˜ค๐˜ข๐˜ฏ ๐˜ข๐˜ญ๐˜ญ ๐˜ฉ๐˜ฆ๐˜ญ๐˜ฑ ๐˜ฎ๐˜ข๐˜ฌ๐˜ฆ ๐˜ฎ๐˜ฆ๐˜ฅ๐˜ช๐˜ค๐˜ช๐˜ฏ๐˜ฆ๐˜ด ๐˜ด๐˜ข๐˜ง๐˜ฆ๐˜ณ.โ€ ๐Ÿ’ŠDid you know that less than 10% of side effects ...
04/11/2025

#๐— ๐—ฒ๐—ฑ๐—ฆ๐—ฎ๐—ณ๐—ฒ๐˜๐˜†๐—ช๐—ฒ๐—ฒ๐—ธ ๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฑ ๐—ถ๐˜€ ๐—ต๐—ฒ๐—ฟ๐—ฒ! ๐Ÿšจ
โ€œ๐˜ž๐˜ฆ ๐˜ค๐˜ข๐˜ฏ ๐˜ข๐˜ญ๐˜ญ ๐˜ฉ๐˜ฆ๐˜ญ๐˜ฑ ๐˜ฎ๐˜ข๐˜ฌ๐˜ฆ ๐˜ฎ๐˜ฆ๐˜ฅ๐˜ช๐˜ค๐˜ช๐˜ฏ๐˜ฆ๐˜ด ๐˜ด๐˜ข๐˜ง๐˜ฆ๐˜ณ.โ€ ๐Ÿ’Š

Did you know that less than 10% of side effects are reported? Every observation counts - from patients to healthcare professionals.
At DrugCard, we help pharmacovigilance specialists spot and analyse adverse reactions in the literature:

๐Ÿ“š Millions of articles monitored globally and locally
โš ๏ธ 2,000+ adverse reaction cases identified
๐Ÿ”Ž Quick and easy searches across languages and regions

This November, your report could save a life. Letโ€™s make medicines safer - together ๐Ÿ‘‰ https://drug-card.io/blog/medsafetyweek-2025-together-we-can-make-medicines-safer/

๐Ÿ’ผ๐—ง๐—ต๐—ถ๐—ป๐—ธ๐—ถ๐—ป๐—ด ๐—ฎ๐—ฏ๐—ผ๐˜‚๐˜ ๐—ฎ ๐—ฐ๐—ฎ๐—ฟ๐—ฒ๐—ฒ๐—ฟ ๐—ถ๐—ป ๐—ฝ๐—ต๐—ฎ๐—ฟ๐—บ๐—ฎ๐—ฐ๐—ผ๐˜ƒ๐—ถ๐—ด๐—ถ๐—น๐—ฎ๐—ป๐—ฐ๐—ฒ? Hereโ€™s what you should know before you start.Pharmacovigilance is often m...
28/10/2025

๐Ÿ’ผ๐—ง๐—ต๐—ถ๐—ป๐—ธ๐—ถ๐—ป๐—ด ๐—ฎ๐—ฏ๐—ผ๐˜‚๐˜ ๐—ฎ ๐—ฐ๐—ฎ๐—ฟ๐—ฒ๐—ฒ๐—ฟ ๐—ถ๐—ป ๐—ฝ๐—ต๐—ฎ๐—ฟ๐—บ๐—ฎ๐—ฐ๐—ผ๐˜ƒ๐—ถ๐—ด๐—ถ๐—น๐—ฎ๐—ป๐—ฐ๐—ฒ?
Hereโ€™s what you should know before you start.
Pharmacovigilance is often misunderstood as simple data entry or reporting adverse events. In reality, itโ€™s a complex field that combines science, regulation, and human impact.

๐Ÿš€The latest DrugCard Blog article explores what truly defines a successful PV specialist:
๐Ÿ”น Critical thinking beyond data collection
๐Ÿ”น Mastering regulatory frameworks and timelines
๐Ÿ”น Balancing routine with responsibility
๐Ÿ”น Developing communication and decision-making skills
๐Ÿ”น Staying current with research, AI tools, and global safety updates

๐Ÿ”ฅIf youโ€™re entering the world of PV (or still recovering from your last PSUR), this blog is for you: https://drug-card.io/blog/what-you-should-know-before-starting-a-career-in-pharmacovigilance/

๐—ง๐—ต๐—ฒ ๐—ณ๐˜‚๐˜๐˜‚๐—ฟ๐—ฒ ๐—ผ๐—ณ ๐—ฝ๐—ต๐—ฎ๐—ฟ๐—บ๐—ฎ๐—ฐ๐—ผ๐˜ƒ๐—ถ๐—ด๐—ถ๐—น๐—ฎ๐—ป๐—ฐ๐—ฒ ๐—ถ๐˜€ ๐—ต๐—ฒ๐—ฟ๐—ฒ โ€” ๐—ฎ๐—ป๐—ฑ ๐—ถ๐˜ ๐—ฟ๐—ฒ๐—ฎ๐—ฑ๐˜€ ๐—ณ๐—ผ๐—ฟ ๐˜†๐—ผ๐˜‚!Imagine never missing an important article and saving hou...
21/10/2025

๐—ง๐—ต๐—ฒ ๐—ณ๐˜‚๐˜๐˜‚๐—ฟ๐—ฒ ๐—ผ๐—ณ ๐—ฝ๐—ต๐—ฎ๐—ฟ๐—บ๐—ฎ๐—ฐ๐—ผ๐˜ƒ๐—ถ๐—ด๐—ถ๐—น๐—ฎ๐—ป๐—ฐ๐—ฒ ๐—ถ๐˜€ ๐—ต๐—ฒ๐—ฟ๐—ฒ โ€” ๐—ฎ๐—ป๐—ฑ ๐—ถ๐˜ ๐—ฟ๐—ฒ๐—ฎ๐—ฑ๐˜€ ๐—ณ๐—ผ๐—ฟ ๐˜†๐—ผ๐˜‚!
Imagine never missing an important article and saving hours of manual work. Sounds futuristic? Itโ€™s already happening with AI in pharmacovigilance literature monitoring.

๐Ÿš€Our latest DrugCard blog post shows how AI speeds up screening, extracts key data, and enables smarter collaboration โ€” all in real time.

๐Ÿ’ก Whether youโ€™re just starting to automate your literature monitoring or exploring AI-powered tools, this post shows how the right technology can make your work faster, smarter, and more accurate.

Check out the full article here ๐Ÿ‘‰ https://drug-card.io/blog/who-reads-all-the-pharmacovigilance-literature-for-you-with-ai/

๐—ช๐—ต๐—ฒ๐—ป ๐—ฅ๐—ฎ๐—ฟ๐—ฒ ๐——๐—ถ๐˜€๐—ฒ๐—ฎ๐˜€๐—ฒ๐˜€ ๐— ๐—ฒ๐—ฒ๐˜ ๐—ฅ๐—ฎ๐—ฟ๐—ฒ ๐—ฆ๐—ฎ๐—ณ๐—ฒ๐˜๐˜† ๐——๐—ฎ๐˜๐—ฎRare diseases affect only a small ๐Ÿ‘ฅgroup of patients, which means limited incent...
14/10/2025

๐—ช๐—ต๐—ฒ๐—ป ๐—ฅ๐—ฎ๐—ฟ๐—ฒ ๐——๐—ถ๐˜€๐—ฒ๐—ฎ๐˜€๐—ฒ๐˜€ ๐— ๐—ฒ๐—ฒ๐˜ ๐—ฅ๐—ฎ๐—ฟ๐—ฒ ๐—ฆ๐—ฎ๐—ณ๐—ฒ๐˜๐˜† ๐——๐—ฎ๐˜๐—ฎ
Rare diseases affect only a small ๐Ÿ‘ฅgroup of patients, which means limited incentives to develop treatments and, unfortunately, limited safety data once those treatments reach the market.

๐ŸŽฏBecause orphan drugs target such small populations, adverse reactions are often underreported or go unnoticed. Thatโ€™s why post-marketing pharmacovigilance is vital in uncovering real-world safety signals.

๐Ÿ“šEven local medical literature monitoring can reveal valuable insights - cases that might never appear in global databases but are crucial for understanding the accurate safety profile of these rare therapies.
๐Ÿ‘‰Discover more in our latest DrugCard blog post: https://drug-card.io/blog/orphan-drugs-and-what-makes-their-pharmacovigilance-unique/

Address

Tallinn

Alerts

Be the first to know and let us send you an email when DrugCards posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to DrugCards:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram